Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07313436 · ClinicalTrials.gov registry record · NA

Extended Release Protein Dosing

A NA study of Nutrition, sponsored by VitaKey.

Recruiting
Registry status
NA
Development phase
21
Enrollment target
1
Study location

NCT07313436: Recruiting NA study of Nutrition, sponsored by VitaKey.

NCT07313436 is a NA study of Nutrition that is actively recruiting participants, run by VitaKey. The registered enrollment target is 21 participants, below the 3,208-participant average among 22 other Nutrition trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07313436, a NA study of Nutrition, is actively recruiting participants, sponsored by VitaKey.

RECRUITING
Registry status
NA
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

The overall goal of this study is to determine the minimum dose required to elicit measurable elevation of plasma essential amino acid levels 12 hours after consuming VitaKey's extended release protein technology. The results of this study will be used to set a dose for future protein clinical studies.

Conditions Studied

Interventions

  • OTHER Control
  • OTHER Extended release nutritional protein
  • OTHER Negative Dose

Study Locations (1)

Illinois

  • Biofortis - Addison

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2025-11-17
Est. Completion 2026-04
Phase NA
VitaKey

1 total trials

What NCT07313436 shows while recruiting

NCT07313436 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 3,208-participant average among 22 other Nutrition trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Nutrition appearing as the primary indexed condition, and to 3 interventions - of which Control is the first listed.

NCT07313436 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT07313436 about?

NCT07313436 is a clinical study titled "Extended Release Protein Dosing". The overall goal of this study is to determine the minimum dose required to elicit measurable elevation of plasma essential amino acid levels 12 hours after consuming VitaKey's extended release protein technology. The results of this study will be used to set a dose for future protein clinical studi...

What is the current status of trial NCT07313436?

This trial is currently recruiting. It is a NA study. The enrollment target is 21 participants. The study started on 2025-11-17. Estimated completion is 2026-04.

What conditions does trial NCT07313436 study?

This clinical trial studies the following conditions: Nutrition.

What interventions are being tested in trial NCT07313436?

The interventions under investigation include: Control (OTHER), Extended release nutritional protein (OTHER), Negative Dose (OTHER).

Who is sponsoring clinical trial NCT07313436?

This trial is sponsored by VitaKey, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07313436 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nutrition

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07313436's enrollment target sits among peer trials

21 22nd of 22 higher than 1 of 22 other Nutrition trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Nutrition trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07313436, the US trial registry maintained by the National Library of Medicine. NCT07313436 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.